title: Increased Plasmodium falciparum gametocyte production in mixed infections with P. malariae.
abstract: Plasmodium falciparum and P. malariae occur endemically in many parts of Africa. Observations from malariotherapy patients suggest that co-infection with P. malariae may increase P. falciparum gametocyte production. We determined P. falciparum gametocyte prevalence and density by quantitative nucleic acid sequence-based amplification (QT-NASBA) after antimalarial treatment of Kenyan children with either P. falciparum mono-infection or P. falciparum and P. malariae mixed infection. In addition, we analyzed the relationship between mixed species infections and microscopic P. falciparum gametocyte prevalence in three datasets from previously published studies. In Kenyan children, QT-NASBA gametocyte density was increased in mixed species infections (P = 0.03). We also observed higher microscopic prevalences of P. falciparum gametocytes in mixed species infections in studies from Tanzania and Kenya (odds ratio = 2.15, 95% confidence interval = 0.99-4.65 and 2.39, 1.58-3.63) but not in a study from Nigeria. These data suggest that co-infection with P. malariae is correlated with increased P. falciparum gametocytemia.
authors.affiliation: Department of Medical Microbiology, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands. t.bousema@ncmls.ru.nl
authors.forename: J Teun
authors.initials: JT
authors.lastname: Bousema
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Drakeley
authors.forename: Petra F
authors.initials: PF
authors.lastname: Mens
authors.forename: Theo
authors.initials: T
authors.lastname: Arens
authors.forename: Rein
authors.initials: R
authors.lastname: Houben
authors.forename: Sabah A
authors.initials: SA
authors.lastname: Omar
authors.forename: Louis C
authors.initials: LC
authors.lastname: Gouagna
authors.forename: Henk
authors.initials: H
authors.lastname: Schallig
authors.forename: Robert W
authors.initials: RW
authors.lastname: Sauerwein
mesh_terms: D000655:Amodiaquine / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use; D002648:Child; D004338:Drug Combinations; D005718:Gametogenesis / Q000502:physiology*; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology*; D010963:Plasmodium falciparum / Q000502:physiology*; D010965:Plasmodium malariae / Q000502:physiology*; D011739:Pyrimethamine / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine